A medical breakthrough may be born in a California laboratory, but whether the resulting factories, high-paying jobs, and long-term capital investment remain in the state is an open question that its political leaders can no longer afford to dodge.
According to Western Journal, that question should be front and center for any American who believes this country ought to manufacture more of what it invents, particularly in the life sciences. Developing a new therapy is an extraordinary scientific feat, but converting that discovery into durable productive capacity is what ultimately strengthens the nation, its workforce, and its industrial base.
California begins this race with a commanding lead, backed by decades of research infrastructure and private capital. According to Biocoms 2026 economic impact report, the states life sciences industry generated $394 billion in economic output in 2025, directly employed more than 406,000 workers, and attracted $73.1 billion in private investment.
Those figures describe a sector whose reach extends far beyond Silicon Valley and well past Californias borders. Yet they also mask a troubling reality: Investment alone does not guarantee expanding opportunity for workers or communities.
A separate 2026 report from California Life Sciences found that employment in the sector had declined 1.8 percent, a warning sign that should cool the self-congratulation in Sacramento. A state can remain a magnet for capital while its workers face a shrinking horizon, and policymakers who claim to champion equity ought to care about both sides of that ledger.
Californias structural advantages are undeniable: world-class research universities, seasoned entrepreneurs, deep scientific talent, and investors willing to finance long-shot projects that may take years to pay off. The real test is whether the state can make building and scaling a business within its borders as attractive as launching one there in the first place.
Palo Alto-based BridgeBio offers a telling example of what is at stake. Its drug Attruby treats adults with transthyretin amyloid cardiomyopathy, also known as ATTR-CM, a serious disease in which abnormal protein deposits damage the heart.
Attrubys approval in 2024 gave patients another treatment option for a condition that can lead to heart failure, and has quickly become a blockbuster drug, generating over $400 million in revenue for the company in the first half of 2026 alone. BridgeBios success highlights the central economic question California must answer: How can the state translate scientific and commercial victories into a broader expansion of opportunity for its own workers?
Companies that bring new therapies to market need an environment that supports the next phase of their growth, not just the research stage. That means access to skilled employees, room to expand, and a predictable, rational path for building out manufacturing and related operations.
For policymakers, the objective should be to make California a place where firms have compelling reasons to deepen their investment rather than shift it to friendlier states or overseas. The states role in developing a breakthrough treatment should mark the beginning of a longer economic story, not the end of it.
Other firms across the state demonstrate just how broad that opportunity could be if leaders chose to nurture it. Pleasanton-based 10x Genomics supplies tools that help make future discoveries possible, and its Atera platform allows researchers to examine gene activity across tissue at large scale, helping them investigate the biology underlying disease.
On Sept. 3, Carlsbad-based Ionis Pharmaceuticals announced FDA approval of Zanvastro, the first disease-modifying treatment for Alexander disease, a rare, progressive, and often fatal neurological disorder that can deprive children and adults of the ability to move independently or swallow. In August, Redwood City-based Revolution Medicines announced FDA approval of Rasonque for certain adults with metastatic pancreatic cancer, reporting that in a Phase 3 trial involving previously treated patients, the medicine reduced the risk of death by 60 percent compared with chemotherapy.
For families facing these devastating diagnoses, progress is measured in treatment options and precious time together, not in press releases or political talking points. That human purpose should remain at the center of any debate over how to regulate, tax, and support the life sciences sector.
Delivering these therapies at scale requires highly trained people, specialized facilities, and reliable production capacity, all of which can anchor middle-class jobs if policymakers do not drive them away. California should be working to capture more of that opportunity within its borders, while Washington should recognize how vital this industry is to Americas broader industrial strength and strategic independence.
Local governments, in particular, need to stop treating employers as adversaries and start providing clarity. They should establish clear permitting requirements and firm timelines for research and manufacturing facilities, because companies must know what approval entails and when a decision will arrive, and predictability and rigorous safety standards can coexist.
Colleges and employers should collaborate on training programs that are explicitly tied to real hiring needs rather than ideological fads. Paid apprenticeships and technical programs could help more Californians qualify for laboratory, production, and equipment maintenance roles that do not require a Ph.D. but still offer solid wages and advancement.
The economic promise of medical innovation should be accessible to those pursuing practical credentials as well as those chasing advanced degrees. A conservative approach would emphasize pathways into productive work, not endless schooling subsidized by taxpayers and burdened by bureaucracy.
Taxpayers, meanwhile, deserve accountability whenever public money is put on the line. Any incentive package should include measurable investment and hiring commitments, transparent public reporting, and real consequences when recipients fail to deliver on their promises.
Federal policymakers also have responsibilities they can no longer ignore. Research funding should be predictable, awarded on scientific merit rather than political fashion, and subject to meaningful oversight, while private investors who risk capital to develop commercial products should not be punished by confiscatory taxes or regulatory whiplash.
Public research can help establish the scientific foundations on which commercial products depend, and both public and private efforts deserve policies that reward useful work and responsible stewardship instead of bureaucratic empire-building. A nation that wants to remain a leader in medicine cannot afford a federal government that treats innovators as a convenient target for regulation and revenue.
California, for its part, cannot assume that its reputation and climate will secure its future in this sector. Entrepreneurs and investors have options, from Texas and Florida to right-to-work states in the Midwest and South, and state leaders must give them concrete reasons to build, manufacture, and hire in the Golden State rather than elsewhere.
BridgeBios success and the advances emerging across California show what American medical innovation can deliver when talent, capital, and freedom to operate come together. The next challenge is to create conditions in which that progress supports a stronger domestic workforce and manufacturing base instead of fueling yet another wave of offshoring.
America should remain capable not only of discovering new medicines but also of producing them on its own soil, under its own laws, and for the benefit of its own citizens. California has helped demonstrate what American science can accomplish; its next test is whether more American workers can build stable, prosperous futures around that success rather than watching those opportunities migrate to more welcoming states or foreign competitors.
Login